Functional activities of 20 human immunodeficiency virus type 1 (HIV-1)-specific human monoclonal antibodies. NLM AIDSLINE Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Functional activities of 20 human immunodeficiency virus type 1 (HIV-1)-specific human monoclonal antibodies.

AIDS Res Hum Retroviruses. 1995 Sep;11(9):1095-9. Unique Identifier : AIDSLINE MED/96089216
Forthal DN; Landucci G; Gorny MK; Zolla-Pazner S; Robinson WE Jr; Department of Medicine, University of California, Irvine College; of Medicine, Orange 92668, USA.

Abstract: Antibodies that are useful in the treatment of HIV infection should result in virus neutralization or lysis of infected cells but should not enhance infection. In this study, the potential clinical use of 20 HIV-1-specific human monoclonal antibodies (HuMAbs) was determined by measuring their enhancing (C-ADE) activities using HIVLAI as the target virus. Two HuMAbs mediated both C-ADE and ADCC, two exclusively neutralized, and five exclusively mediated ADCC. Ten HuMAbs demonstrated no activity in any of the three assays. Three antibodies that neutralized HIVLAI were tested against HIVSF2; all three also neutralized HIVSF2. Four of five HuMAbs mediating ADCC against HIVLAI that were also tested against HIVSF2 had ADCC activity against HIVSF2. These results demonstrate that many HuMAbs have unique functions, allowing the separation of potentially beneficial and harmful activities. Combinations of HuMAbs with ADCC and neutralizing functions may have therapeutic utility.
Keywords: Antibodies, Monoclonal/*PHARMACOLOGY/THERAPEUTIC USE Antibody Specificity Antibody-Dependent Cell Cytotoxicity Cell Line Complement/METABOLISM Human HIV Antibodies/*PHARMACOLOGY/THERAPEUTIC USE HIV Infections/IMMUNOLOGY/THERAPY HIV-1/*IMMUNOLOGY Neutralization Tests JOURNAL ARTICLEKWDantibodies,monoclonal/KWDpharmacology/therapeuticuseantibodyspecificityantibody-dependentcellcytotoxicitycelllinecomplement/metabolismhumanhivantibodies/KWDpharmacology/therapeuticusehivinfections/immunology/therapyhiv-1/KWDimmunologyneutralizationtestsjournalarticle
960530
M9651090

Copyright © 1996 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .